Barbara S. Gillespie, MD, MMS, FASN, is a board-certified nephrologist who completed her residency in internal medicine at the University of North Carolina (UNC) and her nephrology fellowship at Duke University Medical Center. She is currently a Vice President at Labcorp Drug Development where she is the Therapeutic Head of Nephrology and continues to support sponsors on their clinical development and trials for kidney diseases. She is also an Adjunct Professor at the University of North Carolina, Division of Nephrology and Hypertension. Barbara currently serves on the Board of Directors for the Kidney Health Initiative, and NephroNet. She is on the Steering Committee for the NKF CKD Patient Network (Registry) and on the Stakeholder Engagement Group for PREPARE-NS (an FDA grant funded effort to define COAs for Nephrotic Syndrome)

Prior to Labcorp, Barbara worked at Quintiles (currently known as IQVIA) for 11 years, and most recently reported directly to the Chief Medical and Scientific Officer to support issues related to strategy, science, ethics and governance, with a focus on Medical Expertise Integration. She is a past Head of the North American Internal Medicine Medical Teams & was a team leader for 8 physicians reporting to her. As a Global Nephrology Lead she led CKD & ESRD trials from protocol development to trial execution, serving as a consultant to sponsors for Clinical Development Plans, Due Diligence, Regulatory submissions, Commercialization Plans, Health Economics Outcomes Research and Patient Reported Outcomes. Her roles also included Executive Sponsor on a Strategic Partnerships and member on Steering Committees and an Scientific Ad Boards.

She has participated in several Advisory Boards and/or Stakeholder Panels including the 2018 FDA/EMA/NKF Workshop on Renal Endpoints (Stakeholder Committee), NKF/ NKF CKD Registry (Scientific Ad Board) , Workgroup Co Chair for the NKF/FDA Workshop (Dec. 2020) and for NephCure/FDA Clinical Trial Collaborative (2018), UNC's PCORI grant on Building Research Capacity in the Dialysis Community (Stakeholder Advisory Panel), and the global Standardized Outcomes for Nephrology (SONG) Initiative. Barbara has also served on an Independent Endpoint Adjudication Committee for a global CKD and CV Outcomes program.

She is a past Associate Medical Director at a small local dialysis unit, a current Fellow of the American Society of Nephrology, and received board certification in Internal Medicine in 2004 and in Nephrology in 2006 & 2015